Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hang Lung Group Limited stock logo
HNLGY
Hang Lung Group
$8.13
+11.4%
$7.03
$5.28
$8.13
$7.32B0.1315 shs365 shs
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
$104.49
$90.69
$34.26
$105.60
$1.88B0.221,266 shs2,500 shs
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
$24.38
-1.2%
$24.38
$18.50
$31.96
$6.64B1.811,665 shs200 shs
thyssenkrupp AG stock logo
TKAMY
thyssenkrupp
$9.71
+0.1%
$10.36
$3.08
$11.99
$6.04B1.25111,325 shs34,450 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hang Lung Group Limited stock logo
HNLGY
Hang Lung Group
0.00%+11.37%+16.14%+17.91%+43.01%
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
0.00%+0.86%+29.15%+2.36%+235.45%
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
0.00%0.00%0.00%0.00%0.00%
thyssenkrupp AG stock logo
TKAMY
thyssenkrupp
0.00%+0.83%+4.63%-3.38%+118.20%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Hang Lung Group Limited stock logo
HNLGY
Hang Lung Group
N/AN/AN/AN/AN/AN/AN/AN/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
0.3562 of 5 stars
0.03.00.00.03.00.00.0
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
N/AN/AN/AN/AN/AN/AN/AN/A
thyssenkrupp AG stock logo
TKAMY
thyssenkrupp
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hang Lung Group Limited stock logo
HNLGY
Hang Lung Group
0.00
N/AN/AN/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
4.00
Strong BuyN/AN/A
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
0.00
N/AN/AN/A
thyssenkrupp AG stock logo
TKAMY
thyssenkrupp
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest PHMMF, SWTUY, TKAMY, and HNLGY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/31/2025
thyssenkrupp AG stock logo
TKAMY
thyssenkrupp
Kepler Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hang Lung Group Limited stock logo
HNLGY
Hang Lung Group
$1.51B4.85$0.50 per share16.12$20.09 per share0.40
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
$171.15M11.00$0.45 per share231.27$11.62 per share8.99
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
$763.19M8.71$0.70 per share34.66$2.88 per share8.47
thyssenkrupp AG stock logo
TKAMY
thyssenkrupp
$38.01B0.16$1.21 per share8.04$18.05 per share0.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hang Lung Group Limited stock logo
HNLGY
Hang Lung Group
$276.02MN/A0.00N/AN/AN/AN/A7/28/2025 (Estimated)
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
$1.23MN/A0.00N/AN/AN/AN/A7/28/2025 (Estimated)
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
$134.73M$0.5048.7616.931.3025.75%29.63%18.74%N/A
thyssenkrupp AG stock logo
TKAMY
thyssenkrupp
-$1.63B-$1.80N/AN/A-3.63%-11.24%-4.18%8/14/2025 (Estimated)

Latest PHMMF, SWTUY, TKAMY, and HNLGY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q2 2025
thyssenkrupp AG stock logo
TKAMY
thyssenkrupp
$0.2803$0.26-$0.0203$0.26$8.55 billion$9.62 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Hang Lung Group Limited stock logo
HNLGY
Hang Lung Group
$0.799.72%N/AN/AN/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
N/AN/AN/AN/AN/A
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
N/AN/AN/AN/AN/A
thyssenkrupp AG stock logo
TKAMY
thyssenkrupp
$0.090.93%N/AN/A N/A

Latest PHMMF, SWTUY, TKAMY, and HNLGY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2025
Hang Lung Group Limited stock logo
HNLGY
Hang Lung Group
$0.39917.39%5/8/20255/9/20256/26/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hang Lung Group Limited stock logo
HNLGY
Hang Lung Group
0.34
0.71
N/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
0.14
2.55
2.01
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
N/AN/AN/A
thyssenkrupp AG stock logo
TKAMY
thyssenkrupp
0.06
1.76
1.15

Institutional Ownership

CompanyInstitutional Ownership
Hang Lung Group Limited stock logo
HNLGY
Hang Lung Group
N/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
N/A
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
N/A
thyssenkrupp AG stock logo
TKAMY
thyssenkrupp
N/A

Insider Ownership

CompanyInsider Ownership
Hang Lung Group Limited stock logo
HNLGY
Hang Lung Group
N/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
1.88%
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
N/A
thyssenkrupp AG stock logo
TKAMY
thyssenkrupp
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Hang Lung Group Limited stock logo
HNLGY
Hang Lung Group
4,200899.85 millionN/ANot Optionable
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
50918.01 millionN/ANot Optionable
SWEDISH ORPHAN/S stock logo
SWTUY
SWEDISH ORPHAN/S
902272.51 millionN/ANot Optionable
thyssenkrupp AG stock logo
TKAMY
thyssenkrupp
98,120622.50 millionN/ANot Optionable

Recent News About These Companies

Thyssenkrupp zieht Umbau durch und stoppt Spekulationen!

New MarketBeat Followers Over Time

Media Sentiment Over Time

Hang Lung Group stock logo

Hang Lung Group OTCMKTS:HNLGY

$8.13 +0.83 (+11.37%)
As of 06/13/2025 11:26 AM Eastern

Hang Lung Group Limited, an investment holding company, operates as a property developer in Hong Kong and the Mainland of China. The company operates through Property Leasing and Property Sales segments. It develops properties for sale and lease, such as large-scale commercial, office, and residential developments. The company also invests in and develops various properties, including shopping malls, office premises, residential and industrial premises, and car parking bays. In addition, its investment properties portfolio includes Grand Gateway 66, a commercial, office, and residential complex, as well as Plaza 66, a commercial and office complex in Shanghai; Palace 66 and Forum 66 in Shenyang; Parc 66 in Jinan; Center 66 in Wuxi; Riverside 66 in Tianjin; Olympia 66 in Dalian; Spring City 66 in Kunming; and Heartland 66 in Wuhan. Further, the company offers car park and property management, financial, management, project management, and property agency services, as well as operates and manages apartment. Hang Lung Group Limited was incorporated in 1960 and is headquartered in Central, Hong Kong.

Pharma Mar stock logo

Pharma Mar OTCMKTS:PHMMF

$104.49 0.00 (0.00%)
As of 06/13/2025

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.

SWEDISH ORPHAN/S stock logo

SWEDISH ORPHAN/S OTCMKTS:SWTUY

$24.38 -0.29 (-1.18%)
As of 04/9/2019

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

thyssenkrupp stock logo

thyssenkrupp OTCMKTS:TKAMY

$9.71 +0.01 (+0.10%)
As of 06/13/2025 03:56 PM Eastern

thyssenkrupp AG operates as an industrial and technology company in Germany and internationally. It operates through five segments: Automotive Technology, Decarbon Technologies, Materials Services, Steel Europe, and Marine Systems. The Automotive Technology segment offers components, systems, and automation solutions for vehicle manufacturing, such as axle assembly, body in white, camshafts and electric engine components, dampers, dies, springs and stabilizers, crankshafts and conrods, steering, and undercarriages. The Decarbon Technologies segment provides slewing bearings and rings, green ammonia and methanol, chemical and cement plants, high pressure processing, and refinery services, as well as green hydrogen. The Marine System segment manufactures submarines, naval services, and naval surface vessels. The Material Services segment offers 3D-printing/additive manufacturing, alloys, infrastructure project and services, industrial minerals, logistics services, metals, nonferrous metals, plastics, rolled steel, special ores, and stainless steel. The Steel Europe segment manufactures composite materials, electrical steel, hot strips, organic coated strips and sheet, packaging steel, precision steel strip, and sheet and coated products. thyssenkrupp AG was founded in 1811 and is headquartered in Essen, Germany.